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Introduction
G protein-coupled receptors (GPCRs) are pervasive to most physiological and endocrinological processes. Their necessity in maintaining endocrine homeostasis makes them a lucrative therapeutic target, with approximately 40% of current prescription drugs targeting a GPCR. Resulting pathophysiological disorders caused by GPCR dysfunction drives our need to dissect the basic science underpinning the complex modalities of GPCR regulation. Furthermore, understanding these processes is paramount to more targeted and efficacious next generation pharmaceuticals and to personalized medicine approaches (1) .
Homo/heteromerization of GPCR is now a widely accepted modality of how GPCRs regulate their physiological functions (1, 2) . The current evolved model of GPCR signaling incorporates the ever-increasing complexity in GPCR signal pathways and mechanisms of regulation, to which homo/heteromerization has made a significant contribution. Although most studies have documented homo/heteromerization using heterologous cell lines, several studies have demonstrated the in vivo significance of these receptor-receptor interactions. Such complexity in receptor regulation provides key mechanism/s for the multiple and dynamic roles these receptors play in vivo.
This review will discuss the functional and in vivo evidence for GPCR heteromers in endocrine systems. We will describe the criteria for assessing and classifying GPCR heteromers, review their known functional impact from both in vitro and in vivo studies of these hetero-complexes on endocrine function.
Detecting and classifying GPCR heteromers-an overview
GPCR heteromerization is defined as a macromolecule complex composed of at least two receptor units, with biochemical properties that are demonstrably different from those of its individual components (2) . With an increase in the number of reports identifying GPCR heteromers, the resulting challenges in distinguishing the difference between receptors localised to the same cell undergoing functional crosstalk, versus receptors complexed as physiologically relevant heteromers became an important distinction. Thus, three consensus criteria were published by the International Union of Basic and Clinical Pharmacology to facilitate the classification of true GPCR heteromers (3) . The first of these criteria concerns the requirement for evidence of physical receptor-receptor interactions in native or primary tissue.
Traditionally, methods such as co-immunoprecipitation and resonance energy transfer techniques (4) (5) (6) (7) (8) have been used to demonstrate receptor-receptor interactions and hence the proximal existence of heteromers. Recent technological advances in super-resolution and single molecule imaging present an innovative methodology for detecting GPCR heteromers. Techniques such as fluorescent correlation spectroscopy (9,10), single particle tracking via total internal-reflection fluorescent microscopy (11) (12) (13) and localization microscopy techniques such as photoactivated localization microscopy (14, 15) have been utilised to identify GPCR heteromers and homomers. Likewise, proximity ligation assays (PLA), also provide a mechanism for identifying heteromers in native tissues (16) .
The second consensus criteria requires there to be heteromer-specific properties, be it a change in the pharmacology of the receptors via G protein specificity or allosteric binding properties, or ligands that are heteromer-specific. This is demonstrated via classical biochemical, pharmacological and cell signaling techniques to determine changes in ligand binding, G protein-dependent and G protein-independent signal activation. The third criteria necessitates the requirement for the direct physiological evidence for the importance of the identified heteromer. Methodology used to determine this include RNA interference or in vivo studies to introduce genetic modifications in receptor protomers participating in the heteromer. If the transmembrane interface is known, expression or incubation of cell permeable peptides corresponding to the transmembrane region have been employed in vitro and in vivo. Thus, confirming the physiological requirement for the heteromer (2, 3) .
In practice, there are very few identified heteromers that fit all three criteria; with criteria three often the hardest to fulfil given that most functional heteromers have been identified using heterologous cell lines. Therefore, fulfilment of two out of three of the criteria are required for the acceptance of a GPCR heteromer. With respect to endocrine systems, most identified GPCR heteromers that fulfil all three inclusion criteria are neuroendocrine in nature. The functional significance of which will be discussed in further detail.
Impact of GPCR heteromers on receptor activity in endocrine systems
The canonical view of GPCR signaling has evolved from a ligand binding to a single monomeric receptor that activates a single heterotrimeric G protein, to one of growing complexity. GPCR homo/heteromerization provides a modality whereby receptors can mediate multiple functions via modulating receptor trafficking (both exo-and endocytosis), ligand specificity and functional selectivity. In obligatory heteromers such as the GABAB1 and GABAB2 receptors, (also observed with the sweet and umami taste receptors (17) (18) (19) ), the functional significance of heteromerization is required for cell surface expression of both receptors, as well as G protein-coupling (20) (21) (22) , via transactivation of GABAB1-GABAB2 heteromers.
However, identifying the functional significance of GPCR heteromers are not always essential to all functions mediated by a specific receptor. That said, heteromer formation can increase the spectrum of ligand recognition and signal outcomes of a receptor. One common mode of regulation within a heteromer is via allosterism, the outcome of which can lead to distinct functional responses to that of the individual receptors. Broadly speaking, allosteric interactions within heteromers can lead to three different functional outcomes:
1. Ligand binding. Ligand binding within a heteromer results in either positive or negative cooperativity exerted on the neighbouring receptor(s) within the heteromer.
2. G protein recruitment. G protein selectivity may change or exert differential preferences between heteromeric and homomeric complexes. Many GPCR heteromers have been shown to have direct roles in endocrine homeostasis, impacting metabolism, reproduction, nutritional status and stress responses ( Table 1 ). The functional significance of such heteromers has largely been dissected using heterologous cell lines, examples of which will be discussed below.
Metabolism and nutrition
Endocrine-mediated feedback for the control of satiety and appetite is essential for maintaining metabolic homeostasis. Key pathways that regulate appetite stimulation and feeding are mediated via the growth hormone secretagogue receptor (GHSR).
GHSR is expressed within various hypothalamic nuclei involved in food intake and reward-seeking behaviour (reviewed by (23)), and thus has been suggested to be a central player in regulating metabolic homeostasis in both a ligand-dependent (via Ghrelin) and -independent manner, via intrinsic basal GSHR activity (23, 24) . Several studies have demonstrated GHSR to heteromerize with other GPCRs that also regulate metabolic status (23) . Indeed, heteromerization of GSHR and the melanocortin-3 receptor (MC3R) was identified by fluorescence resonance energy transfer (FRET) (25) , with immunohistochemical and in situ studies co-localizing GHSR and MC3R to the arcuate nucleus of the hypothalamus. The functional significance of the GHSR/MC3R heteromers examined in vitro via co-expression of GHSR and MC3R in COS-7 and HEK293 cells, showed that GSHR/MC3R heteromers may enhance MC3R-dependent cAMP accumulation yet decrease basal and ligand-induced GHSR activity. Moreover, the enhanced MC3R activity observed was dependent on the decrease in basal GHSR activity, suggesting positive and negative allosteric regulation between MC3R and GHSR protomers to create functionally asymmetric complexes (26) .
Heteromers of the Class B GPCR family have been suggested to have roles in glucose homeostasis. Ligand-dependent BRET screening of the glucagon receptor family heteromeric and homomeric interactions in HEK293 cells, showed glucagonlike peptide-1 (GLP-1)-dependent heteromer formation between GLP1 and gastricinhibitory polypeptide receptors (GIPR). This heteromeric association was GLP-1specific, with reversal of GLP-1/GIPR association observed with titration of GIPR.
Functionally, a change in the activity of the GLP-1R was also observed in terms of calcium response, and -arrestin recruitment (27) . There has also been recent evidence for functional cross-talk between Gs and Gq-coupled receptors in the regulation of long chain fatty acid mediated incretin secretion. Recent findings have shown that GPR40-mediated GLP-1 release by colonic enteroendocrine cells requires high cAMP levels, achieved via the bile acid receptor TGR5 or GPR119dependent Gs activity (28, 29) . Although these studies suggest functional cross talk at the level of G-protein dependent signaling between Gq-and Gs-coupled GPCRs, whether this is mediated via heteromerization remains to be demonstrated.
Heteromers of vasopressin 1b receptor (V1bR) and corticotrophin releasing hormone receptors (CRHR) have also been demonstrated to be functionally important for mediating the biological functions of their respective hormones. In HEK293 cells, V1bR/CRHR heteromers were shown to act to synergistically enhance the G protein-dependent signal responses. Such enhancement of vasopressin and CRH function could underpin their importance in mediating metabolic responses via adrenocorticotrophin hormone release and insulin secretion (30) .
Reproduction
The gonadotropin receptors follicle-stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHR) are essential for reproduction (31, 32) . Expressed in specialised cellular compartments of the testis and ovary, FSHR and LHR coordinate gonadal steroidogenesis and the production and/or maturation of germ cells (31, 32) . Both FSHR and LHR have been shown to form homomers in vitro (15, (33) (34) (35) (36) (37) (38) . Moreover, using a functional complementation approach, we have shown that transgenic co-expression of ligand-binding deficient LHR and signal deficient LHR could rescue the infertile phenotype of LHR knockout males (33) , thus demonstrating that homomerization is a physiologically relevant mode of LHR function.
Recent studies have also shown that the FSHR and LHR can heteromerize (39,40). Heteromerization has been demonstrated using BRET (40) and fluorescent correlation spectroscopy (39), moreover, heteromerization appears to alter the pharmacology of the LHR and FSHR by enhancing ligand disassociation, and negatively regulating cAMP production (40). LHR/FSHR heteromerization is only physiologically relevant to female reproduction, where co-expression of FSHR and LHR in granulosa cells primarily occurs during the peri-ovulatory period, (41). A defined window of co-expression suggests a role for the heteromer in modulating the pleurotrophic actions of LHR during ovulation. Recent studies have also found that co-treatment of FSH with either hCG or LH can potentiate their respective effects on steroidogenesis and apoptosis (42) . Integration of these findings into the physiological role of LHR and FSHR remains to be demonstrated. Isoforms of the dopamine receptor family have been shown to heteromerize with GHSR. Via TR-FRET and FRET, dopamine D2 receptor (D2R)/GHSR heteromers were demonstrated in vivo within the hypothalamus (44) . Moreover, D2R/GHSR heteromers amplified the anorexigenic effects of D2R. Using cabergoline, the D2Rselective agonist, a dose-dependent suppression of food intake in wild-type and ghrelin knock-out mice was observed, however, there was no effect on food intake in GHSR knock-out mice. These data illustrate that the anorexigenic effects of D2R are augmented by GHSR, presenting a possible avenue for therapeutic interventions in food intake disorders (44) . heteromer formation and activity in fine-tuning and regulating  islet-cell mediated insulin secretion (45) .
In vivo role of GPCR heteromerization to health and disease
A further study has also elucidated the in vivo roles of GHSR/GPR83 heteromers.
GPR83 is an orphan GPCR expressed within hypothalamic nuclei where it controls energy balance, and co-localizes with GHSR in the arcuate nucleus. In vitro analysis using HEK293 cells demonstrated heteromerization of GPR83 and GHSR via BRET (46) . Moreover, in vivo exploration of the physiological role of the GPR83/GHSR heteromers using transgenic knock-out approaches showed that GPR83 knockout mice were protected from weight gain when fed on high-fat diets, despite hyperphagia (46) demonstrating an intriguing role for GPR83 and GHSR heteromers in both feeding behaviour and energy metabolism.
In recent years, several heteromers have been identified with relevance to fetal/maternal health. The intriguing formation of angiotensin 1 receptor (AT1R) and bradykinin 2 receptor (B2R) heteromers were implicated in the pathophysiological development of pre-eclampsia (47, 48) . The expression of AT1R-B2R heteromers were more abundant on platelets and omental vessels isolated from women with preeclampsia, with increased heteromer formation due to the upregulated expression of B2R, resulting in the elevation of angiotensin II-dependent Gq activity.
'Heteromerization can provide a mechanism underlying how the multifaceted functional roles of a single receptor subtype can be mediated. Thus, the identification of GPCR heteromers in vitro, and the functional and physiological validation of heteromers in vivo identifies potential novel therapeutic interventions and drug targets.
Pharmacological exploitation of GPCR heteromers
GPCR heteromers have attracted significant attention from the pharmaceutical industry due to their potential to address the non-specific effects of drugs thought to result from heteromerization, or to exploit the novel properties of heteromers in the design of new therapeutics. The unique biochemical signature of GPCR heteromers, be it a change in trafficking, pharmacology or signaling properties, provide a platform for screening and differential drug targeting. Indeed, well-characterized GPCR heteromers have already been targeted in the development for novel treatment of Parkinson's disease, addiction, schizophrenia, depression and chronic kidney disease. (49) . 'The main strategies to target GPCR heteromers to date are to activate the heteromer specifically via bivalent ligands, using small molecules that target heteromer-specific allosteric binding pockets, or inhibit heteromer function via a drug combination approach, or multifunctional ligands. Bivalent ligands, in the context of GPCR homo/heteromerization, consist of a compound that is selective for one protomer linked by a spacer arm to a compound selective for its partner protomer. These are distinct from bitopic ligands that are compounds able to interact with orthosteric and allosteric sites. Although bitopic (or dualsteric) ligands have been designed based on a monomeric GPCR model, it is certainly possible that these ligands could be designed to be heteromer-specific, although this has not yet been explored for this class of compounds. Bivalent ligands are thought to target and stabilize pre-formed/constitutive heteromers rather than induce heteromerization (51) and have been used as tools to understand the functional significance of specific GPCR heteromers. To date many have been developed towards heteromers containing the μOR. One interesting example is a bivalent ligand that targets the heteromer of μOR/metabotropic glutamate receptor 5
Specific activation of GPCR heteromers
for treatment of chronic inflammatory pain. The compound identified was a μOR agonist coupled to a metabotropic glutamate receptor 5 antagonist and also illustrated that highly defined spacer lengths were key to its activity in vivo (52) . In the context of endocrine systems, bivalent ligands have provided a useful tool to support the clinical and therapeutic relevance of the D2R dopamine receptor/ somatostatin SST2 receptors in acromegaly. These heteromers are expressed in GH-secreting pituitary tumors and have enhanced Gi-signaling activity over their homomeric counterparts (53, 54) . Employment of bivalent ligands, however, demonstrated that targeting both these receptors can effectively inhibit GH and prolactin secretion from GH-secreting pituitary adenomas, more effectively than their response to somatostatin receptor antagonist octreotide (55, 56) . Bivalent ligands have also been developed for the gonadotrophin hormone receptors in order to improve receptor specificity of allosteric low molecular weight compounds to these receptors. Although the study did not assess the compound in the context of LHR/FSHR heterodimers, a small molecular activator of both LHR and FSHR was made more specific to LHR (although resulted in a loss of potency) by linking it with an FSHR-specific negative allosteric modulator (57,58)
Specific pharmacological inhibition of GPCR heteromer function
GPCR heteromers may play a role in the off-target effect of certain drugs and/or have a demonstrated role in human disease, thus selective inhibition of these complexes has been achieved via combination therapy or bi/multifunctional ligands.
A combination therapy approach relevant for endocrine systems is currently in Phase 2 clinical studies for chronic kidney disease. This is based on a therapy to target chemokine receptor CCR2/ angiotensin II type 1A receptor heteromers, repurposing two known antagonists for CCR2 and angiotensin 1A receptor, termed DMX-200 (59) .
Bifunctional or multifunctional peptide ligands could represent an alternate strategy to block action of specific heteromers. These peptide ligands possess agonist activity to one GPCR and antagonistic properties to another. For example, bifunctional ligands that are agonistic at  and/or -opioid receptors yet antagonistic at pro-nociceptive cholecystokinin receptor (60) or substance P neurokinin-1 receptor (61), are thought to create a potent analgesic with fewer side effects than morphine (62), however it is unknown whether such compounds target heteromers of these receptors.
Perspectives
How Furthermore, what is the extent of GPCR heteromerization and how does it contribute to the overall signal crosstalk in cells that express hundreds of distinct GPCRs exposed to multiple ligands? This latter question highlights a functional requirement for crosstalk via heteromerization of GPCRs that contain more than two GPCRs, considering not only oligomeric composition, but also that a heteromer may contain more than two different GPCRs. There is increasing evidence that for certain GPCRs heterotetramers may be the functional form, e.g. D2R-A2A and D2-D3 dopamine receptors, containing equivalent ratios of each GPCR, i.e. association of two homodimers (64) . This is thought to provide a platform for coupling of distinct G proteins, and certainly this is consistent with the idea that functionally asymmetric GPCR oligomers could regulate G protein signal strength (15) . The idea that more than two GPCRs form heteromers has been demonstrated for chemokine receptors (heteromer of CCR2-CCR5-CXCR4) (65) . Such complex associations could be highly significant for endocrine systems where extensive signal crosstalk is exposed 
